Gedatolisib
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Gedatolisib, sold under the brand name Revtorpyk, is an anti-cancer medication used for the treatment of breast cancer. Gedatolisib is a kinase inhibitor. The mechanism of action is accomplished by binding the different p110 catalytic subunit isoforms of PI3K and the kinase site of mTOR. Gedatolisib is administered by intravenous infusion. It was developed by Celcuity, Inc. Gedatolisib was approved for medical use in the United States in July 2026.
Gedatolisib, sold under the brand name Revtorpyk, is an anti-cancer medication used for the treatment of breast cancer. Gedatolisib is a kinase inhibitor. The mechanism of action is accomplished by binding the different p110 catalytic subunit isoforms of PI3K and the kinase site of mTOR. Gedatolisib is administered by intravenous infusion. It was developed by Celcuity, Inc. Gedatolisib was approved for medical use in the United States in July 2026.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1367611707 under CC BY-SA 4.0; modifications have been made.